Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP6 | P55212 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4483879 | 0.85 | CASP6 (0.64) | CASP6MEN1KMT2AGAACYP19A1 | |
| SCHEMBL6907200 | 0.83 | CASP6 (0.61) | CASP6MEN1KMT2ACYP19A1LMNA | |
| SCHEMBL4479011 | 0.83 | CASP6 (0.55) | CASP6MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL6906511 | 0.82 | CASP6 (0.59) | CASP6MEN1KMT2ACYP19A1LMNA | |
| SCHEMBL6909319 | 0.81 | CASP6 (0.61) | CASP6MEN1KMT2AHPGDTP53 | |
| SCHEMBL6903974 | 0.81 | ATM (0.64) | CASP6GAASMN1; SMN2POLB | |
| SCHEMBL6907327 | 0.80 | CASP6 (0.54) | CASP6MEN1KMT2AHPGDGAA | |
| SCHEMBL4449069 | 0.80 | EDNRA (0.51) | MEN1KMT2AHPGDGAANAMPT | |
| SCHEMBL6909638 | 0.79 | CASP6 (0.58) | CASP6MEN1KMT2ATP53CYP19A1 | |
| SCHEMBL4480386 | 0.79 | CASP6 (0.58) | CASP6MEN1KMT2AHPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040234622-A1 | Sulfonamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040234622-A1 | Sulfonamide derivatives | PCNA, TOP2A, DDB1 | CASP6 334/4885MEN1 4723/4885KMT2A 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.